Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers (Q27685364)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

ChEBI release 2020-05-28

ChEBI ID

83404

corrigendum / erratum

Erratum: Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

0 references

author

Ariana Peck

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Mark Merchant

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Daniel J. Anderson

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Christian Wiesmann

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Georgia Hatzivassiliou

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Jacob R Haling

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Huifen Chen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Kyung Song

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Steve Price

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Robert Heald

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Joanne F M Hewitt

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Christine Orr

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Klaus P Hoeflich

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Jocelyn Chan

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Shiuh-Ming Luoh

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Mary J C Ludlam

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Lori S Friedman

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Shiva Malek

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Marcia Belvin

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Mark Zak

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Mark Ultsch

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

language of work or name

English

0 references

publication date

11 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

501

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

7466

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

232-236

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

MEK and the inhibitors: from bench to bedside

7 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

The RAF proteins take centre stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

Novel mitogen-activated protein kinase kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

Understanding organofluorine chemistry. An introduction to the C-F bond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

Negative regulation of MAPKK by phosphorylation of a conserved serine residue equivalent to Ser212 of MEK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

Fully activated MEK1 exhibits compromised affinity for binding of allosteric inhibitors U0126 and PD0325901.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE12441

Deuterium exchange mass spectrometry as a probe of protein kinase activation. Analysis of wild-type and constitutively active mutants of MAP kinase kinase-1

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23934108

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23934108

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NATURE12441

2 references

Consolidated OpenCitations Corpus – April 2017

2249764

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

7 March 2020

1027112082

0 references

2249764

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

2 references

2249764

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23934108%20AND%20SRC:MED&resulttype=core&format=json